Premium
P1‐341: BRAIN VOLUME PREDICTS BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN ALZHEIMER'S DISEASE
Author(s) -
Boublay Nawele,
Bouet Romain,
Dorey Jean-Michel,
Padovan Catherine,
Makaroff Zaza,
Fédérico Denis,
Gallice Isabelle,
Barrellon Marie-Odile,
Robert Philippe,
Moreaud Olivier,
Salmon Pierre Krolak
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.348
Subject(s) - atrophy , dementia , cohort , medicine , neuroimaging , frontal lobe , brain size , alzheimer's disease , disease , temporal lobe , voxel based morphometry , prospective cohort study , psychology , psychiatry , magnetic resonance imaging , white matter , radiology , epilepsy
(FTD), rather than the purely memory and cognitive deficit presentation of typical AD. Methods:Case study methods included analysis of seven patients’ cases with a confirmed mutation on the PSEN-2 gene. The history of illness and disease progression of each patient was reviewed and examined to further identify common symptoms associated with PSEN-2 mutations such as behavioral changes, psychiatric symptoms and memory loss. Results: The participants consisted of six females and one male. Six out of seven patients had a clinical diagnosis of AD between the ages of 51-57 years old, while they presented the first symptom in an age range between 48-56 years. In six out of seven patients, initial symptoms included changes in behavior and personality followed by memory deficits as the disease progressed. Four out of seven patients were diagnosed with depressive/affective disorder and three patients had visual hallucinations. Three patients had previous brain imaging studies in which two of them presented frontal lobe atrophy. All patients had a rapid progression leading to early incapacity on most cases. Conclusions: For the first time, we describe the clinical presentation of a PSEN-2 mutation in seven Puerto Rican patients. Coupled with recent literature, this report suggests that PSEN-2 mutations can present with a mixed AD and FTD clinical criteria, with behavioral changes and psychiatric symptoms being the earliest prominent signs. These findings can guide physicians to recognize that patients with the aforementioned symptoms may have an underlying PSEN-2mutation and may need further evaluation of their families. We believe these results can raise awareness for future studies on PSEN-2 mutation prevalence in the Puerto Rican population.